TEMENOS
8.4.2021 14:02:13 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Salmon Arm Savings and Credit Union (SASCU) has extended its long-standing relationship with Temenos, completing an implementation of the newest functionality of Temenos Analytics to drive its growth strategy. With 20,000 members, and $800 million assets under management, SASCU continues to grow in size and product offerings, using Temenos Analytics to deliver seamless, hyper-personalized digital experiences for its members.
According to a recent report by the Economist Intelligence Unit , improving the account holder experience and engagement is the top strategic priority for financial institutions around the world. SASCU is a forward-looking, community-focused, financial organization driven to provide world-class products and services for all phases of a member’s life. Recognizing the power of data, SASCU has been using Temenos Analytics to drive profitability and strategy for 10+ years as it has grown. Focused on attracting and retaining members, and expanding wallet share through an outstanding experience, SASCU is one of the top performing credit unions in Canada.
Temenos Services Partner ClearSight Solutions collaborated with Temenos to implement additional capabilities at the credit union to modernize the way SASCU uses data with Temenos’ industry-leading funds transfer pricing and activity-based costing capabilities. Leveraging the full strength of Temenos’ powerful reporting tools, SASCU can now calculate the profitability of every member and product using industry best practice financial models in order to identify areas for improvement and new product development. This will enable the credit union to improve financial performance and the member experience.
Over the past five years, online banking visits have nearly doubled. A seamless digital member experience is vital to SASCU’s member acquisition and retention goals. Temenos Analytics is core-agnostic, allowing SASCU to run on a third-party core, break down data silos and improve data accuracy, all with a single view.
Barry Delaney, President and Chief Financial Officer, SASCU Financial Group, commented: “Our vision is to be our members’ lifelong partner – to do that, we need to make sure that we are offering them the products and services they need. Advice and member experience is not one-size-fits-all. We continuously seek new ways of doing things, and for that we need to fully leverage our data. Temenos has enabled us to enhance the range of products we offer in order to deliver better choice, value, and a member-centric experience. By expanding our relationship with Temenos and implementing the enhanced functionality, we will empower our employees to better serve our members, and fully leverage data to drive our strategy.”
Jacqueline White, President, Americas, Temenos, said: “Financial institutions face many challenges such as the acceleration of digital, intense competition, changing account holder behavior, and high operating costs. Continued investment in innovation and technology is vital to success, which is why more than 30 Canadian banks and credit unions partner with Temenos. As a leading provider of banking technology, Temenos enables SASCU to overcome these challenges and create hyper-personalized experiences, ensure higher member satisfaction and increase profits. We’re delighted that, supported by ClearSight’s valuable in-depth business and technical knowledge, SASCU has implemented additional Temenos technology, and we look forward to continuing to support the team as it continues to grow and create meaningful member relationships.”
Michael Zywicki, Partner, ClearSight Solutions, added: “By deploying Temenos Analytics, SASCU demonstrates its understanding that modern tools and data are required to better understand members’ activities and relationship value. ClearSight is excited to be part of this project and to see how SASCU uses the enhanced knowledge of their members to provide them with a differentiated experience.”
– Ends –
About SASCU
SASCU Financial Group offers a broad range of personal and business financial services through SASCU Credit Union and its three lines of business, SASCU Insurance, SASCU Wealth and Commercial banking. SASCU Credit Union branches are in Sicamous and Sorrento, plus two in Salmon Arm. Insurance offices are located in Salmon Arm and Enderby. Established in 1946, SASCU has more than 19,000 members, 150 staff and $900 million in assets. In addition, SASCU stewards $235 million in client investments and serves more than 5000 insurance customers. Learn more at sascu.com .
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business. For more information, please visit www.temenos.com .
About ClearSight
ClearSight Solutions is a Canadian headquartered company with offices in Vancouver, Canada, London, UK and San Jose, Costa Rica whose sole purpose is giving customers the best experience and service they deserve.
As a Temenos Partner, ClearSight provides expert services to deliver on premise or cloud-based data and analytics products. Our mission is to work with customers throughout their data and analytics journey to drive maximum value from their data and analytic investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom